[en] Eighteen years after the birth of the concept, TAVI (Transcatheter Aortic Valve Implantation) has established itself as the treatment of choice for symptomatic patients with severe aortic valve stenosis at high surgical risk. Unlike surgical prosthesis, the benefit of which has been validated in observational studies, indications for TAVI are now based on the results of large randomized trials. The TAVI revolution continues today with the miniaturization of the equipment, the development of new closure systems, the availability of a wider range of prosthesis sizes and the growing experience of operators, all contributing to the widening of indications to lower risk patients.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
LANCELLOTTI, Patrizio ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
NGUYEN TRUNG, Mai-Linh ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
SPRYNGER, Muriel ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
LEMPEREUR, Mathieu ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
MARTINEZ, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > > Service de cardiologie
Language :
French
Title :
Révolution thérapeutique dans le traitement des sténoses aortiques : remplacement valvulaire aortique par voie transcathéter (TAVI).
Alternative titles :
[en] Therapeutic revolution in the treatment of aortic stenosis : transcatheter aortic valve implantation (TAVI ).
Publication date :
May 2020
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Be
Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002;106:3006-8.
Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve mid-term follow-up from the initial feasibility studies: the french experience. J Am Coll Cardiol 2006;47:1214-23.
Baumgartner H, Falk V, Bax J, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017;38:2739-91.
Lancellotti P. L'odyssée de la cardiologie interventionnelle. Rev Med Liege 2019;74:S1-S4.
Martinez C, Gach O, Radermecker MA, et al. Remplacement valvulaire aortique par voie transcathéter: du concept au changement de paradigme dans le traitement des sténoses aortiques. Rev Med Liege 2019;74:S64-S72.
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
Mack M, Leon M, Smith C, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis. Lancet 2015;385:2477-84.
Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014;371:967-8.
Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-20.
Lancellotti P, Kulbertus H. PARTNER-2: TAVI versus chirurgie dans les risques intermédiaires de sténose aortique sévère symptomatique. Rev Med Liege 2016;71:302-7.
Reardon MJ, Adams DH, Kleiman NS, et al. 2-year outcomes in patients undergoing surgical or selfexpanding transcatheter aortic valve replacement. J Am Coll Cardiol 2015;66:113-21.
Thyregod HG, Ihlemann N, Jørgensen TH, et al. Five-year clinical and echocardiographic outcomes from the nordic aortic valve intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation 2019;doi: 10.1161/CIRCULA-TIONAHA.118.036606.
Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.
Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009;119:3009-16.
Lin N, Nores MA, James TM, et al. Alternative access transcatheter aortic valve replacement in nonagenarians versus younger patients. Thorac Cardiovasc Surg 2020;doi: 10.1055/ s-0040-1708478.
Unger P, Lancellotti P, Amzulescu M, et al. Pathophysiology and management of combined aortic and mitral regurgitation. Arch Cardiovasc Dis 2019;112:430-40.
Lancellotti P, Ancion A, Davin L, et al. Le «Heart Team»: définition et organisation. Point de vue du Cardiologue. Rev Med Liege 2019;74:S5-S9.
Daneault B, Kirtane AJ, Kodali SK, et al. Stroke associated with surgical and transcatheter treatment of aortic stenosis: a comprehensive review. J Am Coll Cardiol 2011;58:2143-50.
Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312:162-70.
O'Sullivan CJ, Windecker S. Implications of bicuspid aortic valves for transcatheter aortic valve implantation. Circ Cardiovasc Interv 2013;6:204-6.
Shreenivas S, Kaneko T, Tang GHL. Predicting the future of TAVR: an obituary to open aortic valve replacement? Curr Opin Cardiol 2019;34:112-23.
